EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Larger Non-metastatic No. 8 Lymph Node Size Is Associated With Favorable Prognosis After Pancreaticoduodenectomy for Pancreatic Cancer

TARO SAKAMOTO, TAKESHI GOCHO, MASASHI TSUNEMATSU, YOSHIHIRO SHIRAI, NORIMITSU OKUI, RYOGA HAMURA, YOSHIAKI TANJI, TAKASHI AIDA, YUTA YAMADA, KOHEI OKAZAKI, YUTO YAMAHATA, KENEI FURUKAWA, TORU IKEGAMI

Cancer Diagnosis & Prognosis · 2026-11-01 · 6 (6) · 977-987

DOI: 10.21873/cdp.10600 ↗
AbstractBibliografische Angaben

Abstract

Background/Aim: Although lymph node metastasis is a negative prognostic factor in pancreatic cancer, the significance of non-metastatic lymph node enlargement remains unclear. This study evaluated the prognostic impact of the No. 8 lymph node (N8LN), which is routinely assessed during pancreaticoduodenectomy and identifiable on preoperative imaging. Patients and Methods: We retrospectively reviewed 99 patients who underwent pancreaticoduodenectomy for pancreatic cancer between 2009 and 2019. The size of the N8LN was measured on preoperative imaging, and patients were divided into small and large groups based on the median value. Long-term oncologic outcomes were compared between the two groups. To assess the local immune response, CD8 immunohistochemistry was performed on nodal sections, and CD8⁺ T-cell density was quantified using QuPath software. Results: The large group showed significantly longer progression-free survival (19.7 vs. 9.4 months) and disease-specific survival (41.7 vs. 17.1 months) than the small group. Enlarged N8LN remained an independent favorable prognostic factor in multivariable analysis. CD8⁺ T-cell density did not differ between groups. Conclusion: Enlarged N8LN size was independently associated with better survival after pancreaticoduodenectomy. Nodal enlargement may reflect host immune activity rather than tumor progression and merits further investigation.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →